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Introduction
Magnetic resonance imaging (MRI) of the breast has an 
established role in assessing response to neoadjuvant 
chemotherapy and provides better monitoring of the 
chemotherapeutic eﬀ  ect than clinical breast exami  nation, 
mammography and ultrasound, especially in non-mass 
lesions and tumours that have fragmented into many foci 
[1]. As the overall response rate oﬀ  ered by neoadjuvant 
chemotherapy ranges from 60% to 80%, with complete 
pathological response rates being around 10% to 20% [2], 
identiﬁ  cation of early response is important in planning 
subsequent management. More complex functional MRI 
techniques oﬀ   er to quantify changes in tumour 
microvasculature, cell density, hypoxia, metabo  lism and 
stiﬀ  ness and so provide early predictive and surrogate 
biological biomarkers for monitoring response to 
chemotherapy.
As breast tumours respond to chemotherapy, changes 
occur within the tumour and its microenvironment. 
Angio  genesis, the fundamental physiological process 
asso  ciated with tumour development, is interrupted. Th  e 
composition of the extracellular matrix and stroma is 
altered, and secreted factors and cytokines, which can 
aﬀ  ect the transport of molecules to and from tumour 
cells, change the physiology and chemical composition of 
the tumour. For example, tumour cells become hypoxic 
and fragment, leaving ﬁ  brotic and collagenous tissue that 
may be quantiﬁ  ed using functional magnetic resonance 
(MR) techniques.
Th  is article reviews the functional MR biomarkers of 
response currently routinely available and under develop-
ment for assessing treatment response. Speciﬁ  cally, 
dynamic contrast-enhanced (DCE)-MRI, diﬀ  usion-
weighted (DW)-MRI, intrinsic susceptibility-weighted 
MRI, MR spectroscopy (MRS) and MR elastography are 
described with a focus on the current state of each 
technique and its limitations as a response biomarker.
Dynamic contrast enhanced MRI
DCE-MRI of the breast involves an intravenous injection 
of a low molecular weight T1-shortening paramagnetic 
compound (a gadolinium chelate) at doses between 0.1 
and 0.2 mmol/kg. Agents currently licensed for use 
Abstract
Functional magnetic resonance (MR) encompasses a 
spectrum of techniques that depict physiological and 
molecular processes before morphological changes 
are visible on conventional imaging. As understanding 
of the pathophysiological and biomolecular processes 
involved in breast malignancies evolves, newer 
functional MR techniques can be employed that 
defi  ne early predictive and surrogate biomarkers for 
monitoring response to chemotherapy. Neoadjuvant 
chemotherapy is increasingly used in women with 
primary breast malignancies to down-stage the tumour 
and enable successful breast conservation surgery. 
It also plays a role in the treatment of undetected 
micrometastases. Cardinal physiological features of 
tumours that occur as a result of interactions between 
cancer cells, stromal cells and secreted factors and 
cytokines and how they change with treatment 
provide the opportunity to detect changes in the 
tumour microenvironment prior to any morphological 
change. Through sequential imaging, tumour response 
can be assessed and non-responders can be identifi  ed 
early to enable alternative therapies to be considered. 
This review summarises the functional magnetic 
resonance biomarkers of response in patients with 
breast cancer that are currently available and under 
development. We describe the current state of each 
biomarker and explore their potential clinical uses and 
limitations in assessing treatment response. With the 
aid of selected interesting cases, biomarkers related to 
dynamic contrast-enhanced MRI, diff  usion-weighted 
MRI, T2*/BOLD and MR spectroscopy are described and 
illustrated. The potential of newer approaches, such as 
MR elastography, are also reviewed.
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© 2011 BioMed Central Ltdinclude gadopentetate dimeglumine (Magnevist), gado-
dia  mide (Omniscan), gadobenate dimeglumine (Multi-
hance), gadoteriodol (ProHance), gadofosveset trisodium 
(Vasovist), gadoxetic acid (Eovist) and gadoversetamide 
(OptiMARK). Once injected, gadolinium circulates in the 
blood stream before passing into the extravascular 
extracellular or interstitial space. Th  e concentration of 
gadolinium equilibrates between the intravascular and 
extravascular compartments over time and is eventually 
excreted by the kidneys. Post contrast images provide 
additional information to the unenhanced sequences by 
exploiting diﬀ  erences in temporal enhancement charac-
teristics between malignant and normal or benign 
tissues. Th  e diﬀ  erential uptake and washout of gado  lin-
ium in each of these tissues results in an increased signal 
on T1-weighted (T1W) images. Along with morpho  logical 
assessment from the unenhanced T1W and T2W 
sequences, the use of gadolinium to depict enhancement 
characteristics of the tissues can improve the sensitivity of 
MRI for cancer detection to between 89% and 100% [3].
Along with its high sensitivity, the speciﬁ  city of breast 
DCE-MRI, although initially reported to be low, has 
more recently been shown to equal that of mammography 
with signiﬁ  cantly higher values than ultrasound [4]. Th  e 
blooming sign seen in 63% of malignant compared to 
14.7% of benign lesions describes a brisk enhancement 
with sharply shaped borders at 1 minute after a bolus 
contrast injection that become progressively unsharp [5]. 
Further potential adjunctive morphological indicators of 
malignancy include unifocal oedema (91% of malignant 
lesions and 45% of benign lesions), centripetal enhance-
ment with a rapidly enhancing outer ring that ﬁ  lls in (52% 
malignant lesions [6]), and the hook sign, a hook-like 
connection to the underlying pectoral muscle (33% of 
malignant lesions and 5% of benign lesions [7]). Th  e 
presence of an adjacent vessel on subtraction images is 
also a promising sign for malignancy (85.9% of malignant 
and in situ lesions compared to 19.6% of benign lesions 
[8]). Finally, the addition of morphologic signs from 
unenhanced T2W sequences, such as spiculated margins, 
homogeneous intermediate signal intensity or stellate 
appearance, have been described to further improve the 
speciﬁ  city of breast MRI [8].
Th   e rate of contrast uptake into breast lesions is non-
linear and diﬀ  ers between malignant and benign lesions 
(Figure 1) so that enhancement curve characteristics can 
be used in conjunction with morphologic features to aid 
diﬀ  erential diagnosis. Malignant lesions exhibit stronger 
and faster enhancement than benign changes or normal 
tissues. In benign lesions, a slow onset (type I) curve that 
plateaus after 3 to 5 minutes is described in 83% of cases. 
In malignant lesions, a rapid onset with plateau (type II) 
or rapid onset with washout (type III) curve can be found 
in 91% of cases (57% for type III and 34% for type II) [9]. 
Semi-quantitative parameters can be calculated from 
these enhancement curves, including the onset time 
(from injection to the appearance of contrast in the 
tissues), maximum signal intensity, gradient or rate of 
contrast uptake and washout, and initial area under the 
time signal curve (IAUC).
Quantitative analysis involves pharmacokinetic 
modelling and requires more complex analysis methods 
of estimating changes in tissue contrast agent concen-
tration following intravenous injection. Between 12% and 
45% contrast leaks into the extravascular extracellular 
space (ve) during the ﬁ  rst pass and results in measurable 
T1 shortening of tissues. Th  e transfer constant, Ktrans, 
describes the transendothelial transport of contrast 
medium by diﬀ   usion from the vascular space to the 
tumour interstitium and provides a measure of vascular 
permeability. Over time, gadolinium diﬀ  uses back into 
the vasculature, which can be measured by the rate 
constant, kep. Th  ese parameters are related by the 
equation kep = Ktrans/ve [10] (Figure 2).
Magnetic ﬁ  eld inhomogeneities induced by gadolinium 
on a T2W image can also be exploited to derive relative 
measures of blood ﬂ  ow and volume (rBF and rBV) as well 
as mean transit time (MTT). Th   ese variables are related 
by the central volume theorem equation (BF = BV/MTT). 
Th   e signal loss on a T2W sequence caused by dephasing 
of spins is related to the concentration of gadolinium and 
thus to vessel size and density [11].
Figure 1. Time-signal intensity curve for breast lesions. A type I 
curve shows progressive enhancement in which the signal continues 
to increase over the whole dynamic study. A type II curve plateaus off   
after an initial increase in enhancement. A type III curve demonstrates 
immediate washout after a rapid increase in enhancement.
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measures in breast cancer. Ktrans is generally high in 
tumours, as is kep (Fig. 3), and a signiﬁ  cant reduction of 
up to a third has been shown in both parameters in 
patients with locally advanced breast cancer responding 
early in their course of neoadjuvant chemotherapy [12]. 
In addition, an increase in ve of nearly a third has been 
shown in non-responders [13]. rBV and rBF obtained 
from T2*W dynamic susceptibility sequences have also 
shown reduc  tions of around two-thirds in patients 
responding to treatment [12]; however, T2*W functional 
imaging, while commonly used in MRI of the brain, is 
almost never used in breast MRI. Alterations in these 
parameters are likely to relate to changes in microvessel 
density and function of the microvasculature due to 
antiangiogenic eﬀ   ects of chemotherapy. Th  e evidence 
from phase I and II studies strongly suggests that Ktrans 
can be used as a predictive biomarker to determine 
response to antiangiogenic drugs or vascular disruptive 
agents, with a change in Ktrans of greater than 40% 
considered by many investigators as the threshold 
required to represent deﬁ   nitive disease response [14]. 
Th   ere is some discrepancy in the published data, 
however, with several other studies demonstrating little 
or no decrease in Ktrans or kep following neoadjuvant 
chemotherapy [15,16]; in fact, one small study of 29 
patients scanned very early after one cycle of chemo-
therapy showed that early tumour size change is a better 
response predictor than either Ktrans or kep [17].
Th  e explanation for these variations in reported data 
are multifactorial: patient numbers, tumour type, chemo-
therapeutic agent and time-point of scanning after 
commencing therapy have all varied. Th  e  classiﬁ  cation of 
responders was also not consistent, varying from a 65% 
reduction in the largest tumour volume [13] to the 
accepted Response Evaluation Criteria in Solid Tumours 
(RECIST) or International Union Against Cancer criteria 
[18] of 30% or more reduction in one-dimensional 
tumour size or a 50% or more reduction in the product of 
the tumour diameter (assuming a spherical tumour 
model), respectively [12,15,16]. Th  e group who demon-
strated change in tumour size to be a better predictor of 
response compared to Ktrans or kep chose an arbitrary 
reduction of 15% in one-dimensional size [17].
Th   ere was also a signiﬁ  cant diﬀ  erence in data analysis 
methodology; most studies used manual regions-of-
interest (ROI) on enhanced subtracted images, although 
one group used semi-automated ROI generation, and in 
addition analysed a 3 × 3 pixel ROI hot spot [13]. Further-
more, the median or mean of each pharmacokinetic 
parameter for analysis has not been consistent. An 
increasing awareness of the heterogeneity of breast 
tumours makes the median a more appropriate para-
meter, with the change in the skewness of the distribution 
of these parameters likely to be as signiﬁ  cant as changes 
in the median value.
Another source of variation is the range of mathe-
matical models used for pharmacokinetic analysis and 
the choice of arterial input function measurement, which 
also impacts on the overall results of tumour vascular 
heterogeneity. Traditionally, use of a nearby blood vessel 
for arterial contrast was deemed the ideal arterial input 
function [19], but population-based arterial input func-
tions are more robust [20]. Alternatively, tumour en-
hance  ment relative to that in neighbouring muscle tissue 
can be evaluated [21], and avoids error from ﬂ  ow eﬀ  ects 
in blood vessels. With the introduction of standard  ised 
scanning protocols, automated analysis soft  ware and the 
publication of reproducibility studies, derivation of 
pharmaco  kinetic parameters could become more stan-
dardised and robust and be usefully adopted as functional 
imaging markers in breast cancer.
Diff  usion-weighted MRI
DW-MRI develops intrinsic contrast within tissues based 
on the microscopic motion of water molecules by 
applying magnetic ﬁ  eld gradients during the MRI pulse 
sequence that sensitize the readout signal to losses from 
this motion. DW-MRI contrast provides diﬀ  erent, and 
complementary, information to DCE-MRI, being sensi-
tive to factors that aﬀ  ect this microscopic water motion, 
such as cell density, membrane integrity and tissue 
microstructure. Changes in signal intensity on DW-MRI 
reﬂ  ect the movement of water diﬀ  usion over distances of 
0 to 30 μm over time periods of 50 to 100 ms [22]. As 
with other tumours, breast cancers demonstrate 
restricted diﬀ   usion because water molecules cannot 
move as freely in tissues with a high cell density where 
extracellular space is limited (Figure 4); this results in 
reduced signal loss from Brownian motion and is seen as 
a high signal intensity lesion on the DW-MRI image 
(Figure 5).
Figure 2. Distribution of gadolinium diethylenetriamine penta-
acetic acid (Gd-DTPA) in body compartments after intravenous 
(iv) injection.
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weighting can be varied in their amplitude, duration and 
spacing, which are jointly reﬂ  ected by a ‘b’ value. Acquisi-
tion of DW-MRI data using at least two b values allows 
calculation of an apparent diﬀ  usion coeﬃ   cient (ADC), a 
derived logarithmic parameter of signal change with b 
value. At very low b values (<100 s/mm2), the ADC pre-
dominantly reﬂ  ects larger distances of water move  ment 
likely to represent movement within microvessels. Th  is 
phenomenon is known as intravoxel incoherent motion 
[23]. By eliminating these low b values, this ‘perfusion’ 
eﬀ  ect in vascular rich areas can be suppressed and the 
ADC value can more accurately represent the shorter 
distances travelled by water protons in the extracellular 
space, or true diﬀ  usion [24].
Th   e role of DW-MRI in tumour diagnosis is gradually 
being explored and it is increasingly shown to aid 
decision-making [25]. Diﬀ  erentiation between malignant 
and benign breast lesions using DW-MRI has been well 
reported [26-28], with the mean ADC value of malignant 
lesions being signiﬁ   cantly lower than that of benign 
lesions or normal breast tissue. Th  is degree of overlap 
requires incorporation of an ADC threshold 
methodology for analysis; a 1.6 × 10-3 mm2/s cutoﬀ   gives 
up to 96% sensitivity and 55% speciﬁ   city for tumour 
identiﬁ   cation [27]. More recently, one group has 
normalised ADC values to the surrounding glandular 
tissue and demon  strated a reduction in overlap between 
benign and malig  nant lesions. Using this method, 
normalised ADC values for tumour and benign lesions 
are 0.55 × 10-3 mm2/s and 1.1 × 10-3 mm2/s, respectively) 
[29], with the optimal thres  hold of 1.6 × 10-3 mm2/s 
normalising to 0.7 × 10-3 mm2/s.
Th   e visibility of lesions on DW-MRI is better in older 
women compared to younger women, likely related to the 
density of the glandular parenchyma. Also, due to the 
lower spatial resolution oﬀ  ered by DW-MRI compared to 
DCE-MRI, the diagnostic performance of DW-MRI is 
less helpful for non-mass-like lesions such as invasive 
lobular carcinomas and lesions <1 cm in size [30]. Th  e 
Figure 3. Images showing pharmacokinetic modelling parameters. (a-c) Malignant tumour within the breast illustrated on dynamic contrast-
enhanced MRI and using the vascular parameters: (a) transfer constant (Ktrans); (b) extravascular extracellular space (ve); (c) rate constant from 
extravascular/extracellular space back into plasma (kep). All these parameters are higher at the tumour periphery compared to the centre and in the 
satellite nodule, indicative of more neoangiogenesis in these areas.
(a) (b) (c)
                Ktrans                                     ve                                      kep
Figure 4. Diagram illustrating free and restricted diff  usion of water in diff  erent tissues. ADC, apparent diff  usion coeffi   cient; DWI, diff  usion 
weighted imaging.
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papillomas and ﬁ  brocystic disease, which can also result 
in overestimation of cancer extension [27]. Mucinous 
carcinomas interestingly demonstrate a signiﬁ  cantly 
higher ADC compared to other types of breast cancer, 
leading to false-negative reports [31].
DW-MRI also shows promise as an early surrogate 
biomarker for detecting response to neoadjuvant 
chemotherapy. Induction of successful apoptosis results 
in loss of membrane integrity, alteration of membrane 
barriers to water diﬀ  usion and cell shrinkage, increasing 
extracellular space. Th  is translates to a rise in the ADC 
value of up to 35% and precedes any decrease in tumour 
size in locally advanced tumours [32-34]. Transient early 
decreases in ADC have also been demonstrated before 
this increase, and are thought to be related to cell 
swelling, reduction in blood ﬂ  ow or changes in compo-
sition of the extracellular space [16].
Th   e optimal b values for diﬀ  usion-weighted MRI in the 
breast have not been established; nor indeed have the 
optimal scanning protocol, imaging parameters and 
methods of analysis, which all have a bearing on the ADC 
value. Published data indicate that b values from 0, 600 to 
850, and up to 1,000 may be optimal [27,28,30], with at 
least three values required to ensure robustness of repro-
ducibility of the measurement. Th   e ability to obtain these 
data without the use of extrinsic contrast agents, in a 
short scanning time, independent of magnetic ﬁ  eld 
strength and operator interpretation is hugely advan-
tageous. Reproducibility studies and quality assurance of 
methodology crucially need to be established.
T2*/blood oxygen level-dependent MRI
Blood oxygen level-dependent (BOLD) or intrinsic 
susceptibility-weighted MRI relies on the paramagnetic 
property of deoxyhaemoglobin, which creates suscep-
tibility variations in the magnetic ﬁ  eld (or microscopic 
ﬁ  eld gradients), which in turn decrease the transverse 
relaxation rate R2* ( = 1/T2*) of water in blood and the 
tissue surrounding blood vessels. An increase in the 
deoxyhaemoglobin concentration (that is, hypoxia) leads 
to a decrease in the signal intensity on the T2* image and 
a faster R2* [35] (Figure 6). An improvement in oxygena-
tion has the converse eﬀ  ect. Deoxyhaemoglobin therefore 
acts as an intrinsic BOLD contrast agent for imaging 
tissue hypoxia. Speciﬁ   c gradient-recalled echo (GRE) 
sequen  ces are required to detect changes in R2*. Varia-
tions in R2* have largely been evaluated in xenograft and 
human models using inhaled carbogen (95% oxygen (O2), 
5% carbon dioxide (CO2)) to intensify the otherwise small 
changes in signal intensity: the CO2 induces vasodilation 
and the O2 tension is high with 95% O2 so that subtracted 
images with and without carbogen reveal regions of 
hypoxia where signal change is greatest. Unfortunately, 
the hyperventilation induced by breathing carbogen in 
humans is poorly tolerated so reliance has been largely 
on R2* measurements during air, or alternatively 100% 
oxygen, breathing.
A recent study in breast cancer patients has shown R2* 
values to be signiﬁ  cantly lower in tumour than normal 
breast parenchyma prior to the commencement of 
chemotherapy [36], suggesting that breast tumours are 
less hypoxic than normal breast tissue, possibly because of 
their high vascularity. Th  is contrasts with other recently 
published data in prostate cancer [37], where R2* is 
increased, indicating increased hypoxia in these tumours. 
Th  e increased R2* in normal breast tissue has also been 
related to the ﬁ   brocollagenous ligaments of Cooper, 
which maintain normal breast structural inte  grity and 
contribute to higher R2* values. In responders following 
treatment, the R2* value has been shown to increase, likely 
as a result of decreased blood ﬂ  ow; however, in this one 
published study this parameter was not as eﬃ   cacious as 
changes in other DCE-MRI para  meters, such as Ktrans, 
rBV, and rBF, or even morphological parameters such as 
tumour size, in indicating response [36]. Th  e  complexity 
Figure 5. Diff  usion weighted images of a breast tumour. (a) Sagittal T2W image through the breast shows a well-defi  ned lobulated mass 
inferiorly. (b) This appears as a bright area of restricted diff  usion on the corresponding diff  usion weighted MRI (DW-MRI) image (b = 200). (c) The 
calculated apparent diff  usion coeffi   cient (ADC) map shows the heterogeneity of diff  usion coeffi   cient values within the tumour.
(a) (b)         (c)
          
        T2W image      DWI image b=200                  ADC map
O’Flynn and deSouza Breast Cancer Research 2011, 13:204 
http://breast-cancer-research.com/content/13/1/204
Page 5 of 10and heterogeneity of the micro  vascu  lature in diﬀ  erent 
tumour types thus need to be understood prior to using 
such measurements for evaluating changes in tumour 
oxygenation in response to chemotherapy.
MR spectroscopy
MRS exploits the nuclear spin properties of hydrogen 
(1H) as well as of other atoms with unpaired protons, 
such as 31P,  23Na and 19F, in a magnetic ﬁ  eld to absorb and 
emit radiofrequency. Th  e acquired frequency spectrum 
of a range of metabolites provides information about the 
altered metabolism of cancer cells. With 1H MRS, 
eﬃ     cient water suppression is mandatory to document 
proton resonances within molecules known to be 
increased in cancer, such as choline and lipids; protons 
within these molecules resonate at slightly diﬀ  erent 
frequencies when placed in a magnetic ﬁ  eld because of 
their immediate molecular environment. In breast 
cancer, as with other tumours, high levels of choline-
containing metabolites involved in phospholipid metabo-
lism, and thus cellular membranes in prolifera  tion, result 
in a triplet at 3.22 ppm of free choline, phosphocholine 
and glycerophosphocholine. Choline is virtually un-
detectable in normal breast tissue and a peak at 3.25 ppm 
indicates benign tissue [38].
Several groups have shown that total choline concen-
tration [Cho] can be used as a marker of malignancy, and 
when combined with DCE-MRI, increases the speciﬁ  city 
of breast MR up to 88% (and to 100% after the inclusion 
of a single slice T2* perfusion measurement) [39]. In vivo 
1H-MRS has also been shown to be useful in monitoring 
metabolic response to chemo  therapy, with increased 
[Cho] and water/fat ratios in malignant tumours indica-
tive of residual disease [40]. Small patient studies to date 
show promising results, with reduction of the choline 
signal following two cycles of neoadjuvant chemotherapy 
being more sensitive than changes in tumour size at 
predicting pathological response [41]. Also, by imaging 
after one cycle of chemo  therapy, the same group demon-
strated that a reduction in the choline signal may be more 
sensitive than DW-MRI in demonstrating pathological 
response [41,42].
In vivo 1H MRS is a single, large voxel technique, and 
overall variations in the fat and water composition, 
particularly in heterogenous tumours such as invasive 
lobular cancers and ductal carcinoma in situ, reduces 
sensitivity of [Cho] quantiﬁ  cation. Partial volume eﬀ  ects 
in a large voxel also cause problems in the quantiﬁ  cation 
of [Cho], which pose a signiﬁ  cant problem after neo-
adjuvant chemotherapy [43].
Two dimensional localised correlated sepctroscopy 
(L-COSY MRS) incorporates a second spectral dimen-
sion that is indirectly detected through the acquisition of 
multiple one-dimensional MRS with incrementally 
longer times to echo (TEs). Cross-correlation of peaks 
enables identiﬁ   cation of lipid species by reducing 
contami  nation from overlapping metabolite resonances. 
Early reports have shown identiﬁ  cation of invasive ductal 
carcinoma within these spectra versus normal fatty 
breast tissue with 92.4% sensitivity and 92.7% speciﬁ  city 
[44]. However, the technique is time consuming (20 
minutes for a 3 cm voxel) and requires specialist analysis 
software, so its clinical utility is limited.
Sodium (23Na) MRI has also been shown to be a very 
sensitive indicator of cellular integrity and cellular energy 
metabolism [45], with an elevated tissue sodium concen-
tration in neoplastic tissue. 23Na images can be accurately 
determined by co-registering high-resolution 1H images 
acquired during the same scan. Its potential as a 
surrogate biomarker of response has been reported with 
a signiﬁ   cantly reduced tissue sodium concentration in 
responders after one cycle of chemotherapy [46].
MR elastography
MR elastography, an imaging correlate to palpation, is 
another novel technique that can be easily implemented 
Figure 6. T2*W images of a breast tumour. (a-c) Sagittal T2W (a), dynamic contrast-enhanced (DCE) subtracted image at time point 2.44 minutes 
(b), and T2*W image (c) in a patient with a palpable breast lump in the upper outer quadrant. The tumour seen in (a) and highlighted in (b) shows 
heterogeneity of T2* with faster signal decay in the inferior part of the tumour, indicating a greater deoxyhaemoglobin content here.
(a)                                    (b)    (c)
         
        T2W image             DCE Subtraction image           T2*W image
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of lesions by direct MRI visualisation of acoustic waves 
and quantiﬁ   es the decreased elasticity of malignant 
tumours. Quantiﬁ   cation of the diﬀ  erential  ‘stiﬀ  ness’ 
between a breast lesion and the background adipose and 
ﬁ   broglandular tissues is achieved by assessing the 
propagation of mechanical waves, generated by an 
electromechanical driver, through the breast using a 
gradient echo phase contrast sequence [47]. Th  e tissue 
stiﬀ  ness map (or elastogram) is based on a linear scale, 
calibrated into kilopascals and represented as a colour 
map.
MR elastography can be performed as an extension to 
conventional breast MRI and could potentially be 
incorporated into a standard MRI breast examination. It 
is already being used clinically for the assessment of 
patients with chronic liver disease. Th   ere have been very 
few studies of breast MR elastography; early published 
data on a small population group suggests that MR 
elastography in combination with DCE-MRI could 
increase the diagnostic performance of breast MRI and 
increase its speciﬁ  city from 75% with a persistently high 
sensitivity of 90% [48]. Further investigations of larger 
cohorts and smaller lesions will be necessary to validate 
these results.
Discussion
In patients with breast cancer, traditional anatomical 
imaging using size and morphological criteria for assessing 
response to neoadjuvant chemotherapy does not provide 
information on functional changes within tumours. Th  e 
current challenge is to move beyond these anatomical 
boundaries to develop a more personalised, individual 
assessment of functional changes within a tumour for 
response evaluation. For those with the poorest prognosis 
and most advanced disease, early identi  ﬁ  cation of non-
responders allows alternative management options to be 
considered. MRI has the versatility to contribute to the 
functional assessment of breast tumours and improve 
diagnostic conﬁ  dence, as well as provide early surrogate 
markers of disease response.
Functional MRI biomarkers of response described need 
careful validation, ideally against clinical outcome 
measures, before they can be adopted as established 
surrogate end points of response. However, currently an 
insuﬃ   cient number of clinical studies have been reported 
with this kind of data for this to happen; reported 
changes are summarised in Table 1. Multicentre valida-
tion against histopathological markers, such as for micro-
vessel density, apoptosis, hypoxia and vascularity, would 
further qualify the use of these functional biomarkers 
and support their translation into clinical practice. 
However, histological validation lacks true ‘functional’ 
input, so the limitation of this kind of validation needs to 
be recognised: it may well be that MRI on its own may 
more accurately reﬂ  ect in vivo tumour physiology.
In an attempt to tackle the issues of validation, two 
phase II multicentre national trials are underway - Neo-
COMICE in the United Kingdom and I-SPY 2 in the US, 
both of which are examining the eﬀ  ectiveness of MRI in 
the early prediction of response to neoadjuvant chemo-
therapy and the development of surrogate imaging 
biomarkers. Neo-COMICE, currently in its pilot stage, 
also aims to evaluate the optimal scanning protocols that 
determine parameters of greatest predictive value of 
treat  ment response and establish parity of MRI exami-
ations between centres. Currently, there is no consensus 
on a standardized MR imaging examination or on the 
role of MRI for assessing response in patients receiving 
neoadjuvant chemotherapy. Th  e adaptive design of the 
I-SPY 2 trial will allow early data from one set of patients 
to guide decisions about which treatments may be more 
useful in the trial in order to eliminate ineﬀ  ective 
treatments and oﬀ   er patients the best chance of 
successful therapy [49].
Th   e increased availability of higher-ﬁ  eld MRI scanners 
allows higher signal-to-noise ratio and so better spatial 
resolution to increase the visibility of small cancers. Early 
reports suggest that the sensitivity and speciﬁ  city  of 
DCE-MRI at 3T for malignant breast lesions increase to 
95% and 91%, respectively, from 91% and 85% [50]. Going 
up in ﬁ  eld strength from the commonly available 1.5T to 
3.0T is not without challenges, however, as the non-
uniformity of the magnetic induction ﬁ  eld (B1) results in 
non-homogeneity of fat suppression, which in turn leads 
to poor enhancement in areas with a very low magnetic 
induction ﬁ  eld and errors in quantifying enhancement 
ratios. Reports have shown that the B1 ﬁ  eld in one breast 
can be reduced by as much as 40%, which is suﬃ   cient to 
reduce the conspicuity of a malignant lesion and reduce 
the sensitivity to cancer detection [51]. Quantitative 
functional MRI at 3T requires improved radiofrequency 
excitation methods and improved analysis to ensure B1 
inhomogeneity is accounted for when calculating DCE 
metrics.
Future potential in the search for biomarkers of eﬃ   cacy 
for certain therapeutic treatments may lie in correlating 
baseline gene expression with MRI response using several 
of the above techniques. Gene arrays and immuno  histo-
chemistry analysis of vascular endothelial growth factor 
pathways could indicate which pattern of gene expression 
relates to speciﬁ   c changes in vascular volume and 
permeability assessed by MRI, and this is a promising 
area of research [52].
Ongoing research and recent technical advances 
indicate that the prospects for substantial improvements 
in monitoring of therapeutic response as well as for 
improved early detection and accurate diagnosis of breast 
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of development indicating early translation to routine 
clinical care. A key factor in their success will depend on 
rigorous quality control and assurance to ensure that the 
quantitative measurements are robust and reproducible.
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